HC Wainwright Reiterates Buy Rating on Harmony Biosciences, Sets $55 Target
HC Wainwright reiterated its Buy rating and $55 price target. The target implies 43.9% upside from the Oct. 12 close of $38.23.
Story updates
10:49:04 AM UTC
SquawkNews
Harmony Biosciences Price Target Maintained With a $55.00/Share by HC Wainwright & Co.